Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced breast cancer: drug shows promise against brain tumors

NCT ID NCT04739761

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the drug by IV infusion every three weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
trastuzumab deruxtecan (a targeted antibody-drug combination)
What this could lead to
If successful, this could confirm trastuzumab deruxtecan as an effective treatment for advanced HER2-positive breast cancer, including in patients with brain metastases.
What could go wrong
This is an early-phase study (3b/4) and results may not confirm long-term benefit. Side effects can include lung inflammation, nausea, and low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    Durham, North Carolina, 27710, United States

  • Research Site

    Adelaide, 5000, Australia

  • Research Site

    Auchenflower, 4066, Australia

  • Research Site

    Clayton, 3168, Australia

  • Research Site

    Heidelberg, 3084, Australia

  • Research Site

    St Leonards, 2065, Australia

  • Research Site

    Subiaco, 6008, Australia

  • Research Site

    Anderlecht, 1070, Belgium

  • Research Site

    Bruges, 8000, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Liège, 4000, Belgium

  • Research Site

    Vancouver, British Columbia, V5Z 1H7, Canada

  • Research Site

    Toronto, Ontario, M4N 3M5, Canada

  • Research Site

    Copenhagen, 2100, Denmark

  • Research Site

    Herlev, 2730, Denmark

  • Research Site

    Odense C, 5000, Denmark

  • Research Site

    Helsinki, 00290, Finland

  • Research Site

    Tampere, FI-33521, Finland

  • Research Site

    Turku, 20520, Finland

  • Research Site

    Berlin, 13125, Germany

  • Research Site

    Dresden, 1307, Germany

  • Research Site

    Erlangen, 91054, Germany

  • Research Site

    Essen, 45136, Germany

  • Research Site

    Frankfurt, 60389, Germany

  • Research Site

    Hamburg, 20246, Germany

  • Research Site

    Hanover, 30625, Germany

  • Research Site

    Kiel, 24105, Germany

  • Research Site

    Mannheim, 68167, Germany

  • Research Site

    München, 80336, Germany

  • Research Site

    München, 80637, Germany

  • Research Site

    Münster, 48149, Germany

  • Research Site

    Tübingen, 72076, Germany

  • Research Site

    Cork, T12 DV56, Ireland

  • Research Site

    Dublin, 7, Ireland

  • Research Site

    Dublin, D04 Y8V0, Ireland

  • Research Site

    Ancona, 60122, Italy

  • Research Site

    Bergamo, 24127, Italy

  • Research Site

    Catania, 95126, Italy

  • Research Site

    Milan, 20132, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Padova, 35128, Italy

  • Research Site

    Prato, 59100, Italy

  • Research Site

    Isehara, 259-1193, Japan

  • Research Site

    Kawasaki-shi, 216-8511, Japan

  • Research Site

    Sapporo, 003-0804, Japan

  • Research Site

    Shinagawa-ku, 142-8666, Japan

  • Research Site

    Yokohama, 241-8515, Japan

  • Research Site

    Maastricht, 6229 HX, Netherlands

  • Research Site

    The Hague, 2545 AA, Netherlands

  • Research Site

    Bergen, 5009, Norway

  • Research Site

    Oslo, 450, Norway

  • Research Site

    Oslo, N-0379, Norway

  • Research Site

    Gdansk, 80-214, Poland

  • Research Site

    Krakow, 31-501, Poland

  • Research Site

    Opole, 45-060, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Warsaw, 04-141, Poland

  • Research Site

    Lisbon, 1400-048, Portugal

  • Research Site

    Lisbon, 1649-035, Portugal

  • Research Site

    Porto, 4099-001, Portugal

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Barcelona, 8035, Spain

  • Research Site

    Bilbao (Vizcaya), 48013, Spain

  • Research Site

    Granada, 18014, Spain

  • Research Site

    Madrid, 28005, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Salamanca, 37007, Spain

  • Research Site

    Santander, 39008, Spain

  • Research Site

    Santiago de Compostela-Coruña, 15706, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Valencia, 46009, Spain

  • Research Site

    Gothenburg, 413 45, Sweden

  • Research Site

    Lund, 221 85, Sweden

  • Research Site

    Uppsala, 751 85, Sweden

  • Research Site

    Basel, 4031, Switzerland

  • Research Site

    Bellinzona, CH-6500, Switzerland

  • Research Site

    Lausanne, 1011, Switzerland

  • Research Site

    Lucerne, 6000, Switzerland

  • Research Site

    Edinburgh, EH4 2XR, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.